Colistin Methanesulfonate Sodium Inhalation for Prophylaxis of Ventilator-Associated Pneumonia (CIVAP): A Prospective, Multicentre, Double-Blind, Randomized, Placebo-Controlled Trial

NARecruitingINTERVENTIONAL
Enrollment

508

Participants

Timeline

Start Date

July 15, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2026

Conditions
Ventilator-Associated Pneumonia (VAP)
Interventions
DRUG

Colistimethate sodium (CMS)

CMS (colistimethate sodium, 75mg, solubilized in 4 mL 0.9% saline), twice daily. Nebulization will be performed using a vibrating mesh nebulizer (Aeroneb solo, Aerogen, Galway, Ireland) placed in the inspiratory limb of the ventilator tubing, behind the Y-piece, and continued until the nebulizer deposit becomes dry for three consecutive days of mechanical ventilation. To ensure the experiment is conducted under blind conditions, the Nebulizer will be covered by stickers. A filter will be placed on the expiratory limb to protect the ventilator.

Trial Locations (1)

250000

RECRUITING

Qilu Hospital of Shandong university, Jinan

All Listed Sponsors
lead

Qilu Hospital of Shandong University

OTHER

NCT06834971 - Colistin Methanesulfonate Sodium Inhalation for Prophylaxis of Ventilator-Associated Pneumonia (CIVAP): A Prospective, Multicentre, Double-Blind, Randomized, Placebo-Controlled Trial | Biotech Hunter | Biotech Hunter